日本語フィールド
著者：Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S題名：Discontinuation of dasatinib in chronic myeloid leukaemia patients who have maintained deep molecular response for more than 1 year: the prospective, multicentre Dasatinib Discontinuation (DADI) Trial.発表情報：Lancet Haematol. 巻: 2 号: 12 ページ: e528-35キーワード：概要：抄録：英語フィールド
Author：Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura STitle：Discontinuation of dasatinib in chronic myeloid leukaemia patients who have maintained deep molecular response for more than 1 year: the prospective, multicentre Dasatinib Discontinuation (DADI) Trial.Announcement information:Lancet Haematol. Vol: 2 Issue: 12 Page: e528-35